Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

American Journal of Transplantation · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles